Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Endocrine 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 3Small Cell Lung Carcinoma 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Metastatic Bladder Urothelial Carcinoma 1Leiomyosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Advanced Solid Tumor 1

Interventions

Everolimus 7avelumab 3Temozolomide 3Etoposide 3Cisplatin 3Bevacizumab 3pembrolizumab 2gallium Ga 68 dotatate 2azaspirane 2Irinotecan 2veliparib 1tocilizumab 1selinexor 1pralsetinib 1pertuzumab 1pasireotide 1lenvatinib 1irinotecan sucrosofate 1carfilzomib 1berzosertib 1belinostat 1Topotecan 1TLC 388 1Radiotherapy 1Radiosurgery 1Radionuclide Imaging 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1Podophyllotoxin 1Platinum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Neuroendocrine × berzosertib × Clear all
NCT02487095 2025-04-13

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
62 enrolled 29 charts
EndocrineGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡